Accounting for Interim Safety Monitoring of an Adverse Event Upon Termination of a Clinical Trial

By Dallas Michael  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 4, 2008-07 ,pp. : 631-638

Taylor & Francis Ltd

Access to resources Recommend Favorite

Safety and adverse event profile of duloxetine

By Wernicke Joachim F   Gahimer James   Yalcin Ilker   Wulster-Radcliffe Meghan   Viktrup Lars  

Expert Opinion on Drug Safety, Vol. 4, Iss. 6, 2005-11 ,pp. : 987-993

Informa Healthcare

Access to resources Recommend Favorite

A Computerized Adverse Drug Event Alerting System Using Clinical Rules: A Retrospective and Prospective Comparison with Conventional Medication Surveillance in the Netherlands

By Rommers Mirjam K.   Teepe-Twiss Irene M.   Guchelaar Henk-Jan  

Drug Safety, Vol. 34, Iss. 3, 2011-03 ,pp. : 233-242

Adis International

Access to resources Recommend Favorite

A review of the Vaccine Adverse Event Reporting System database

By Geier David A   Geier Mark R  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 691-698

Informa Healthcare

Access to resources Recommend Favorite

Commentary on “Accounting for the Interim Safety Monitoring of an Adverse Event Upon Termination of a Clinical Trial”

By Liu Jen-pei  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 4, 2008-07 ,pp. : 641-643

Taylor & Francis Ltd

Access to resources Recommend Favorite